Table 1 Demographic, laboratory, and clinical variables of 207 LT recipients

Age (year)

46.0 ± 9.8

Gender (%)

Male

Female

172(83.1%)

35(16.9%)

Length of hospital stay before LT (days), median (IQR)

8(1–24)

Preoperative MELD score, median (IQR)

25(16–30)

Antibacterial drug use within 15 days before LT (%)

68(32.8)

Infection within 2 months before LT (%)

99(47.8)

Pulmonary infection

73(35.2)

Abdominal/biliary tract infection

6(2.9)

Bloodstream infection

1(0.5)

Urinary tract infection

1(0.5)

Multisite infection

18(8.7)

Primary disease for LT (%)

Hepatitis B cirrhosis, liver necrosis and liver cancer

156(75.4)

Hepatitis C or E cirrhosis

5(2.4)

Alcoholic cirrhosis

14(6.8)

Autoimmune hepatitis

4(1.9)

Others

19(9.2)

Mixed liver disease

9(4.3)

Preoperative type 2 diabetes (%)

27(13.0)

Preoperative WBC (×10⁹/L), median (IQR))

5.17(3.5–8.08)

Preoperative lymphocyte count (×10⁹/L), median (IQR)

0.82(0.51–1.24)

Preoperative platelet count (×10⁹/L), median (IQR)

65(43–96)

Preoperative albumin (g/L), median (IQR))

33.9(30.5–36.9)

Cold ischemia time of donor (hrs), median (IQR)

5.6(4.1–7.4)

Time of operation (min), median (IQR)

365(335–422)

The intraoperative blood loss (ml), median (IQR)

3000(2000–4200)

The intraoperative RBC transfusion (U), median (IQR)

12.5(9–17)

Postoperative ventilator support (%)

16(7.7)

Transplantation or open laparotomy again (%)

7(3.4)

Postoperative duration of indwelling urethral catheter (days), median (IQR)

3(3–5)

Postoperative methylprednisolone dosage (mg), median (IQR)

1570(1360–1760)

Immunosuppressant (%)

Tacrolimus

206(99.5)

Cyclosporin A

1(0.5)

Mycophenolate mofetil

125(60.4)

Mycophenolate sodium enteric-coated tablets

46(22.2)

Glucocorticoids

207(100)

Antithymocyte globulin

14(6.8)

Basiliximab

144(69.6)

ALT on day 1 after surgery (U/L), median (IQR)

690(395–1185)

Serum creatinine on day 3 after surgery (mg/ml), median (IQR)

0.8(0.7–1.2)

Recipients with bacterial infection (%)

55(26.6)

Gram-negative infection

20(9.7)

Gram-positive infection

23(11.1)

Mixed infection

12(5.8)

Acute rejection (%)

26(12.6)

Deaths (%)

14(6.8)